Subsequently, we applied chemogenetic methods to suppress GLP-1 neurons during EA treatment to observe whether the effects of EA on suppressing food intake, improving obesity, and lipid metabolism were achieved through the specific activation of the "GLP-1—hypothalamus" pathway (Fig. 4A). The gene discussed is GLP1R; the disease is obesity disorder.